{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T02:26:49Z","timestamp":1792895209991,"version":"4.5.0"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T00:00:00Z","timestamp":1755820800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001171","name":"Cancer Institute NSW","doi-asserted-by":"publisher","award":["2020\/CDF1093"],"award-info":[{"award-number":["2020\/CDF1093"]}],"id":[{"id":"10.13039\/501100001171","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.jconrel.2025.114143","type":"journal-article","created":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T16:24:17Z","timestamp":1755620657000},"page":"114143","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Gut microbial diversity is preserved through localised chemo-immunotherapy delivery in a KPC mouse model of pancreatic cancer"],"prefix":"10.1016","volume":"386","author":[{"given":"Elahe","family":"Minaei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Joyce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha J.","family":"Wade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Brownlee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chelsea","family":"Penney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Ranson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morteza","family":"Aghmesheh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Sluyter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara L.","family":"Vine-Perrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2025.114143_bb0005","unstructured":"Upper gastrointestinal (GI) cancer survival rates and statistics. Pancreatic cancer statistics 2021; Available from: https:\/\/www.pancare.org.au\/about\/cancer-statistics\/#:\u223c:text=Pancreatic%20cancer%20statistics,cancer%20related%20deaths%20by%202030."},{"issue":"19","key":"10.1016\/j.jconrel.2025.114143_bb0010","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2025.114143_bb0015","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.3389\/fimmu.2018.01878","article-title":"Immune checkpoint inhibition for pancreatic ductal adenocarcinoma: current limitations and future options","author":"Kabacaoglu","year":"2018","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.jconrel.2025.114143_bb0020","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.ccell.2020.08.004","article-title":"Challenges and opportunities for pancreatic cancer immunotherapy","volume":"38","author":"Bear","year":"2020","journal-title":"Cancer Cell"},{"issue":"15","key":"10.1016\/j.jconrel.2025.114143_bb0025","doi-asserted-by":"crossref","first-page":"4282","DOI":"10.1158\/0008-5472.CAN-17-3821","article-title":"Radiotherapy and CD40 activation separately augment immunity to checkpoint blockade in cancer","volume":"78","author":"Rech","year":"2018","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.jconrel.2025.114143_bb0030","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/S1470-2045(20)30532-5","article-title":"CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study","volume":"22","author":"O\u2019Hara","year":"2021","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.jconrel.2025.114143_bb0035","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13046-022-02273-w","article-title":"Combination therapy for pancreatic cancer: anti-PD-(L) 1-based strategy","volume":"41","author":"Liu","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2025.114143_bb0040","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jconrel.2024.07.023","article-title":"Enhancing pancreatic cancer immunotherapy: leveraging localized delivery strategies through the use of implantable devices and scaffolds","volume":"373","author":"Minaei","year":"2024","journal-title":"J. Control. Release"},{"issue":"6161","key":"10.1016\/j.jconrel.2025.114143_bb0045","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1126\/science.1240527","article-title":"Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment","volume":"342","author":"Iida","year":"2013","journal-title":"science"},{"issue":"3","key":"10.1016\/j.jconrel.2025.114143_bb0050","doi-asserted-by":"crossref","first-page":"16","DOI":"10.20517\/mrr.2022.23","article-title":"Gut microbiota resilience and recovery after anticancer chemotherapy","volume":"2","author":"Roggiani","year":"2023","journal-title":"Microbiom. Res. Rep."},{"key":"10.1016\/j.jconrel.2025.114143_bb0055","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.706331","article-title":"Emerging evidence of the gut microbiome in chemotherapy: a clinical review","volume":"11","author":"Oh","year":"2021","journal-title":"Front. Oncol."},{"issue":"16","key":"10.1016\/j.jconrel.2025.114143_bb0060","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.3390\/cancers13163999","article-title":"Gut microbiota dynamics during chemotherapy in epithelial ovarian cancer patients are related to therapeutic outcome","volume":"13","author":"D\u2019Amico","year":"2021","journal-title":"Cancers"},{"issue":"8","key":"10.1016\/j.jconrel.2025.114143_bb0065","first-page":"6369","article-title":"Dual contribution of the gut microbiome to immunotherapy efficacy and toxicity: supportive care implications and recommendations","volume":"30","author":"Wardill","year":"2022","journal-title":"Support Care Cancer"},{"issue":"1","key":"10.1016\/j.jconrel.2025.114143_bb0070","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1186\/s12967-024-05709-3","article-title":"Influence of the gut microbiota on immune cell interactions and cancer treatment","volume":"22","author":"Liu","year":"2024","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.jconrel.2025.114143_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105966","article-title":"Influence of gut and intratumoral microbiota on the immune microenvironment and anti-cancer therapy","volume":"174","author":"Chen","year":"2021","journal-title":"Pharmacol. Res."},{"issue":"10","key":"10.1016\/j.jconrel.2025.114143_bb0080","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1136\/gutjnl-2020-321153","article-title":"The role of gut microbiota in cancer treatment: friend or foe?","volume":"69","author":"Cheng","year":"2020","journal-title":"Gut"},{"issue":"6356","key":"10.1016\/j.jconrel.2025.114143_bb0085","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1126\/science.aah5043","article-title":"Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine","volume":"357","author":"Geller","year":"2017","journal-title":"Science"},{"issue":"6264","key":"10.1016\/j.jconrel.2025.114143_bb0090","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1126\/science.aad1329","article-title":"Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota","volume":"350","author":"V\u00e9tizou","year":"2015","journal-title":"Science"},{"issue":"6264","key":"10.1016\/j.jconrel.2025.114143_bb0095","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1126\/science.aac4255","article-title":"Commensal Bifidobacterium promotes antitumor immunity and facilitates anti\u2013PD-L1 efficacy","volume":"350","author":"Sivan","year":"2015","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.jconrel.2025.114143_bb0100","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.3390\/cancers15072101","article-title":"The role of the gut microbiome in cancer immunotherapy: current knowledge and future directions","volume":"15","author":"Kiousi","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.jconrel.2025.114143_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106916","article-title":"Akkermansia muciniphila: a potential target and pending issues for oncotherapy","volume":"196","author":"Zhao","year":"2023","journal-title":"Pharmacol. Res."},{"issue":"2","key":"10.1016\/j.jconrel.2025.114143_bb0110","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/s41591-021-01655-5","article-title":"Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer","volume":"28","author":"Derosa","year":"2022","journal-title":"Nat. Med."},{"issue":"6161","key":"10.1016\/j.jconrel.2025.114143_bb0115","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1126\/science.1240537","article-title":"The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide","volume":"342","author":"Viaud","year":"2013","journal-title":"science"},{"issue":"11","key":"10.1016\/j.jconrel.2025.114143_bb0120","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1038\/nrc3610","article-title":"The microbiome and cancer","volume":"13","author":"Schwabe","year":"2013","journal-title":"Nat. Rev. Cancer"},{"issue":"7741","key":"10.1016\/j.jconrel.2025.114143_bb0125","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/s41586-019-0878-z","article-title":"A defined commensal consortium elicits CD8 T cells and anti-cancer immunity","volume":"565","author":"Tanoue","year":"2019","journal-title":"Nature"},{"issue":"Suppl 2","key":"10.1016\/j.jconrel.2025.114143_bb0130","first-page":"1248","article-title":"A localised combinational immunotherapy using an implantable device with systemic chemotherapy towards the treatment of pancreatic cancer","volume":"12","author":"Minaei","year":"2024","journal-title":"BMJ Specialist J"},{"issue":"40","key":"10.1016\/j.jconrel.2025.114143_bb0135","doi-asserted-by":"crossref","first-page":"eabh0363","DOI":"10.1126\/sciadv.abh0363","article-title":"Intravital imaging technology guides FAK-mediated priming in pancreatic cancer precision medicine according to Merlin status","volume":"7","author":"Murphy","year":"2021","journal-title":"Sci. Adv."},{"issue":"21","key":"10.1016\/j.jconrel.2025.114143_bb0140","doi-asserted-by":"crossref","first-page":"2001115","DOI":"10.1002\/adhm.202001115","article-title":"Dual delivery of gemcitabine and paclitaxel by wet-spun coaxial fibers induces pancreatic ductal adenocarcinoma cell death, reduces tumor volume, and sensitizes cells to radiation","volume":"9","author":"Wade","year":"2020","journal-title":"Adv. Healthc. Mater."},{"issue":"5","key":"10.1016\/j.jconrel.2025.114143_bb0145","first-page":"23","article-title":"Ethylene oxide sterilization update","volume":"6","author":"Barker","year":"1995","journal-title":"Med. Device Technol."},{"issue":"19","key":"10.1016\/j.jconrel.2025.114143_bb0150","doi-asserted-by":"crossref","first-page":"10255","DOI":"10.3390\/ijms251910255","article-title":"Gut microbiota disruption in hematologic cancer therapy: molecular insights and implications for treatment efficacy","volume":"25","author":"Guevara-Ram\u00edrez","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2025.114143_bb0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13099-019-0299-4","article-title":"Gut microbiome associated with chemotherapy-induced diarrhea from the CapeOX regimen as adjuvant chemotherapy in resected stage III colorectal cancer","volume":"11","author":"Fei","year":"2019","journal-title":"Gut pathogens"},{"issue":"1","key":"10.1016\/j.jconrel.2025.114143_bb0160","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13568-022-01428-4","article-title":"Presence of Akkermansiaceae in gut microbiome and immunotherapy effectiveness in patients with advanced non-small cell lung cancer","volume":"12","author":"Grenda","year":"2022","journal-title":"AMB Express"},{"issue":"1","key":"10.1016\/j.jconrel.2025.114143_bb0165","doi-asserted-by":"crossref","first-page":"3","DOI":"10.20517\/mrr.2023.51","article-title":"Understanding the role of gut microfloral bifidobacterium in cancer and its potential therapeutic applications","volume":"3","author":"Sharma","year":"2023","journal-title":"Microbiom. Res. Rep."},{"issue":"6","key":"10.1016\/j.jconrel.2025.114143_bb0170","doi-asserted-by":"crossref","first-page":"4211227","DOI":"10.21037\/apm-20-2183","article-title":"The gut microbiome can be used to predict the gastrointestinal response and efficacy of lung cancer patients undergoing chemotherapy","volume":"9","author":"Zhang","year":"2020","journal-title":"Ann. Palliative Med."},{"issue":"6371","key":"10.1016\/j.jconrel.2025.114143_bb0175","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.aan3706","article-title":"Gut microbiome influences efficacy of PD-1\u2013based immunotherapy against epithelial tumors","volume":"359","author":"Routy","year":"2018","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.jconrel.2025.114143_bb0180","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0039743","article-title":"Human intestinal lumen and mucosa-associated microbiota in patients with colorectal cancer","volume":"7","author":"Chen","year":"2012","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.jconrel.2025.114143_bb0185","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/s41591-024-02803-3","article-title":"Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma","volume":"30","author":"Bj\u00f6rk","year":"2024","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.jconrel.2025.114143_bb0190","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/s41591-022-01695-5","article-title":"Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma","volume":"28","author":"Lee","year":"2022","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.jconrel.2025.114143_bb0195","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.eururo.2020.04.044","article-title":"Gut bacteria composition drives primary resistance to cancer immunotherapy in renal cell carcinoma patients","volume":"78","author":"Derosa","year":"2020","journal-title":"Eur. Urol."},{"issue":"5","key":"10.1016\/j.jconrel.2025.114143_bb0200","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/s00262-024-03665-x","article-title":"Bifidobacterium modulation of tumor immunotherapy and its mechanism","volume":"73","author":"Pei","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.jconrel.2025.114143_bb0205","doi-asserted-by":"crossref","first-page":"1159771","DOI":"10.3389\/fcimb.2023.1159771","article-title":"The relationship between gut microbiota and inflammatory response, learning and memory in mice by sleep deprivation","volume":"13","author":"Zhang","year":"2023","journal-title":"Front. Cell. Infect. Microbiol."},{"issue":"10","key":"10.1016\/j.jconrel.2025.114143_bb0210","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1038\/bjc.2013.174","article-title":"Serum levels of IL-6 and IL-1\u03b2 can predict the efficacy of gemcitabine in patients with advanced pancreatic cancer","volume":"108","author":"Mitsunaga","year":"2013","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jconrel.2025.114143_bb0215","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s00280-018-3549-0","article-title":"Influence of gemcitabine chemotherapy on the microbiota of pancreatic cancer xenografted mice","volume":"81","author":"Panebianco","year":"2018","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"4","key":"10.1016\/j.jconrel.2025.114143_bb0220","doi-asserted-by":"crossref","first-page":"979","DOI":"10.3904\/kjim.2018.306","article-title":"Cancer patients with neutropenic septic shock: etiology and antimicrobial resistance","volume":"35","author":"Jung","year":"2019","journal-title":"Korean J. Intern. Med."},{"issue":"3","key":"10.1016\/j.jconrel.2025.114143_bb0225","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1136\/gutjnl-2020-321747","article-title":"Gut microbiome stability and resilience: elucidating the response to perturbations in order to modulate gut health","volume":"70","author":"Fassarella","year":"2021","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.jconrel.2025.114143_bb0230","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s40164-023-00442-x","article-title":"Role of gut microbiome in cancer immunotherapy: from predictive biomarker to therapeutic target","volume":"12","author":"Zhang","year":"2023","journal-title":"Exp. Hematol. Oncol."},{"issue":"2","key":"10.1016\/j.jconrel.2025.114143_bb0235","doi-asserted-by":"crossref","first-page":"236","DOI":"10.4161\/cbt.27222","article-title":"Irinotecan disrupts tight junction proteins within the gut: implications for chemotherapy-induced gut toxicity","volume":"15","author":"Wardill","year":"2014","journal-title":"Cancer Biol. Ther."},{"issue":"5","key":"10.1016\/j.jconrel.2025.114143_bb0240","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s00280-012-1989-5","article-title":"Chemotherapy-induced gut toxicity: are alterations to intestinal tight junctions pivotal?","volume":"70","author":"Wardill","year":"2012","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"11","key":"10.1016\/j.jconrel.2025.114143_bb0245","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1002\/ijc.28656","article-title":"TLR4\/PKC-mediated tight junction modulation: a clinical marker of chemotherapy-induced gut toxicity?","volume":"135","author":"Wardill","year":"2014","journal-title":"Int. J. Cancer"},{"issue":"11","key":"10.1016\/j.jconrel.2025.114143_bb0250","first-page":"5059","article-title":"Prediction of mucositis risk secondary to cancer therapy: a systematic review of current evidence and call to action","volume":"28","author":"Wardill","year":"2020","journal-title":"Support Care Cancer"},{"issue":"6120","key":"10.1016\/j.jconrel.2025.114143_bb0255","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1126\/science.1232467","article-title":"Host-derived nitrate boosts growth of E. Coli in the inflamed gut","volume":"339","author":"Winter","year":"2013","journal-title":"science"},{"key":"10.1016\/j.jconrel.2025.114143_bb0260","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.biomaterials.2016.06.032","article-title":"Inducing enhanced immunogenic cell death with nanocarrier-based drug delivery systems for pancreatic cancer therapy","volume":"102","author":"Zhao","year":"2016","journal-title":"Biomaterials"},{"issue":"19","key":"10.1016\/j.jconrel.2025.114143_bb0265","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.3390\/cells11193033","article-title":"Immunogenic cell death: an emerging target in gastrointestinal cancers","volume":"11","author":"Chiaravalli","year":"2022","journal-title":"Cells"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925007540?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925007540?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T08:43:01Z","timestamp":1777192981000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365925007540"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":53,"alternative-id":["S0168365925007540"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.114143","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gut microbial diversity is preserved through localised chemo-immunotherapy delivery in a KPC mouse model of pancreatic cancer","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.114143","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"114143"}}